Revvity (RVTY) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed Revvity (RVTY) over the past year, gaining 540.3% versus a gain of 65.8%. Over five years, RVTY leads with a -10.4% price change compared with -49.2% for TXG. Revvity is the larger company by market cap ($16.98 billion vs $10.07 billion), about 1.7 times the size, while 10x Genomics is growing revenue faster (+5.2% vs +3.7%).
On valuation, Revvity trades at a lower forward P/E (25.8x vs 1008.0x for 10x Genomics). Revvity pays a dividend yielding 0.18%, while 10x Genomics does not currently pay one. Revvity converts more of its revenue into profit, with a net margin of 8.4% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RVTY | TXG |
|---|---|---|
| Share price | $152.16 | $77.28 |
| Market cap | $16.98B | $10.07B |
| 1-day change | -0.94% | +1.55% |
| YTD return | +57.27% | +373.82% |
| 1-year return | +65.81% | +540.27% |
| 5-year return | -10.40% | -49.25% |
| P/E ratio (TTM) | 72.80 | — |
| Forward P/E | 25.82 | — |
| EPS (TTM) | $2.09 | $-0.59 |
| Dividend yield | 0.18% | 0.00% |
| Annual dividend | $0.28 | $0.00 |
| Revenue (latest FY) | $2.86B | $642.82M |
| Revenue growth (YoY) | +3.67% | +5.25% |
| Net income (latest FY) | $241.20M | $-43.54M |
| Gross margin | — | 69.05% |
| Operating margin | 12.49% | -9.49% |
| Net margin | 8.45% | -6.77% |
| 52-week high | $166.25 | $102.81 |
| 52-week low | $81.22 | $11.16 |
| Distance from 52-week high | -8.48% | -24.83% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -10.71% | -12.69% |
| Average volume | 1.79M | 3.29M |
| Shares outstanding | 111.59M | 120.21M |
| Employees | 11,000 | 1,178 |
| Sector | Industrials | Healthcare |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXG has outperformed RVTY by 474.5 percentage points over the past year.
- Revvity is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
- The two companies sit in different sectors: Revvity in Industrials and 10x Genomics in Healthcare.
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Healthcare · Medical Devices · 1,178 employees
RVTY vs TXG FAQ
Which is bigger, Revvity or 10x Genomics?
Revvity (RVTY) is larger, with a market capitalization of $16.98B compared with $10.07B for 10x Genomics (TXG).
Which stock has performed better over the past year, RVTY or TXG?
TXG returned +540.27% over the past 12 months, compared with +65.81% for RVTY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Revvity or 10x Genomics?
Revvity pays a dividend yielding 0.18%, while 10x Genomics does not currently pay a regular dividend.
Are Revvity and 10x Genomics in the same industry?
No. Revvity is in the Industrials sector, while 10x Genomics is in Healthcare.